Votubia

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

everolimus

Available from:

Novartis Europharm Limited

ATC code:

L01XE10

INN (International Name):

everolimus

Therapeutic group:

Aġenti antineoplastiċi

Therapeutic area:

Sklerosi Tuberuża

Therapeutic indications:

Renali angiomyolipoma assoċjati ma tuberi-kumpless sklerożi (TSC)Votubia huwa indikat għall-kura ta 'pazjenti adulti b'indeboliment tal-kliewi angiomyolipoma assoċjati ma tuberi-kumpless sklerożi (TSC) li huma f'riskju ta' kumplikazzjonijiet (ibbażata fuq fatturi bħad-daqs tat-tumur jew il-preżenza ta anewriżma, jew il-preżenza ta'bosta jew bilaterali tumuri) iżda li ma tkunx teħtieġ kirurġija immedjata. L-evidenza hija bbażata fuq l-analiżi tal-bidla fil-qosor tal-volum angiomyolipoma. Subependymal ċellula ġgant anaplastika (SEGA) assoċjati ma 'l-isklerożi multipla tat-tuberi kumplessa (TSC)Votubia huwa indikat għall-kura ta' pazjenti b'subependymal ċellula ġgant anaplastika (SEGA) assoċjati ma ' l-isklerożi multipla tat-tuberi kumplessa (TSC) li jeħtieġu l-intervent terapewtiku iżda mhumiex soġġetti għall-kirurġija. L-evidenza hija bbażata fuq l-analiżi tal-bidla fil-volum SEGA. Ulterjuri tal-benefiċċju kliniku, bħal xi titjib fis-mard relatat mal‑sintomi, ma ntweriex.

Product summary:

Revision: 30

Authorization status:

Awtorizzat

Authorization date:

2011-09-02

Patient Information leaflet

                                1
ANNESS 1
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
_ _
Votubia 2.5 mg pilloli
Votubia 5 mg pilloli
Votubia 10 mg pilloli
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Votubia 2.5 mg pilloli
Kull pillola fiha 2.5 mg everolimus.
_Eċċipjent b’effett magħruf _
Kull pillola fiha 74 mg lactose.
Votubia 5 mg pilloli
Kull pillola fiha 5 mg everolimus.
_Eċċipjent b’effett magħruf _
Kull pillola fiha 149 mg lactose.
Votubia 10 mg pilloli
Kull pillola fiha 10 mg everolimus.
_Eċċipjent b’effett magħruf _
Kull pillola fiha 297 mg lactose.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola.
Votubia 2.5 mg pilloli
Pilloli minn bojod sa kemxejn sofor, tawwalin ta’ madwar 10.1 mm
fit-tul x 4.1 mm fil-wisa’, b’ġenb
tasturat u bl-ebda sinjal dritt, imnaqqxin b’“LCL” fuq naħa
waħda u “NVR” fuq in-naħa l-oħra.
Votubia 5 mg pilloli
Pilloli minn bojod sa kemxejn sofor, tawwalin ta’ madwar 12.1 mm
fit-tul x 4.9 mm fil-wisa’, b’ġenb
tasturat u bl-ebda sinjal dritt, imnaqqxin b’“5” fuq naħa
waħda u “NVR” fuq in-naħa l-oħra.
Votubia 10 mg pilloli
Pilloli minn bojod sa kemxejn sofor, tawwalin ta’ madwar 15.1 mm
fit-tul x 6.0 mm fil-wisa’, b’ġenb
tasturat u bl-ebda sinjal dritt, imnaqqxin b’“UHE” fuq naħa
waħda u “NVR” fuq in-naħa l-oħra.
3
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Anġjomijolipoma renali assoċjata ma’ kumpless sklerożi tuberoża
(TSC)
Votubia huwa indikat għat-trattament ta’ pazjenti adulti
b’anġjomijolipoma assoċjata ma’ -TSC li
jinsabu f’riskju ta’ kumplikazzjonijiet (imsejjes fuq fatturi
bħalma huma d-daqs tat-tumur jew
il-preżenza ta’ anewriżmu, jew il-preżenza ta’ tumuri multipli
jew bilaterali) li ma jeħtiġux
operazzjoni immedjata.
L-evidenza tissejjes fuq analiżi tal-bidla fit-total tal-volum
tal-anġjomijolipoma.
Astroċitoma subependimali b’ċellula ġganta (SEGA) assoċjata
ma’- TSC
Votubia huwa indikat għat-trattament ta’ p
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS 1
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
_ _
Votubia 2.5 mg pilloli
Votubia 5 mg pilloli
Votubia 10 mg pilloli
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Votubia 2.5 mg pilloli
Kull pillola fiha 2.5 mg everolimus.
_Eċċipjent b’effett magħruf _
Kull pillola fiha 74 mg lactose.
Votubia 5 mg pilloli
Kull pillola fiha 5 mg everolimus.
_Eċċipjent b’effett magħruf _
Kull pillola fiha 149 mg lactose.
Votubia 10 mg pilloli
Kull pillola fiha 10 mg everolimus.
_Eċċipjent b’effett magħruf _
Kull pillola fiha 297 mg lactose.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola.
Votubia 2.5 mg pilloli
Pilloli minn bojod sa kemxejn sofor, tawwalin ta’ madwar 10.1 mm
fit-tul x 4.1 mm fil-wisa’, b’ġenb
tasturat u bl-ebda sinjal dritt, imnaqqxin b’“LCL” fuq naħa
waħda u “NVR” fuq in-naħa l-oħra.
Votubia 5 mg pilloli
Pilloli minn bojod sa kemxejn sofor, tawwalin ta’ madwar 12.1 mm
fit-tul x 4.9 mm fil-wisa’, b’ġenb
tasturat u bl-ebda sinjal dritt, imnaqqxin b’“5” fuq naħa
waħda u “NVR” fuq in-naħa l-oħra.
Votubia 10 mg pilloli
Pilloli minn bojod sa kemxejn sofor, tawwalin ta’ madwar 15.1 mm
fit-tul x 6.0 mm fil-wisa’, b’ġenb
tasturat u bl-ebda sinjal dritt, imnaqqxin b’“UHE” fuq naħa
waħda u “NVR” fuq in-naħa l-oħra.
3
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Anġjomijolipoma renali assoċjata ma’ kumpless sklerożi tuberoża
(TSC)
Votubia huwa indikat għat-trattament ta’ pazjenti adulti
b’anġjomijolipoma assoċjata ma’ -TSC li
jinsabu f’riskju ta’ kumplikazzjonijiet (imsejjes fuq fatturi
bħalma huma d-daqs tat-tumur jew
il-preżenza ta’ anewriżmu, jew il-preżenza ta’ tumuri multipli
jew bilaterali) li ma jeħtiġux
operazzjoni immedjata.
L-evidenza tissejjes fuq analiżi tal-bidla fit-total tal-volum
tal-anġjomijolipoma.
Astroċitoma subependimali b’ċellula ġganta (SEGA) assoċjata
ma’- TSC
Votubia huwa indikat għat-trattament ta’ p
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 27-06-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 27-06-2022
Public Assessment Report Public Assessment Report Bulgarian 15-06-2018
Patient Information leaflet Patient Information leaflet Spanish 27-06-2022
Public Assessment Report Public Assessment Report Spanish 15-06-2018
Patient Information leaflet Patient Information leaflet Czech 27-06-2022
Public Assessment Report Public Assessment Report Czech 15-06-2018
Patient Information leaflet Patient Information leaflet Danish 27-06-2022
Public Assessment Report Public Assessment Report Danish 15-06-2018
Patient Information leaflet Patient Information leaflet German 27-06-2022
Public Assessment Report Public Assessment Report German 15-06-2018
Patient Information leaflet Patient Information leaflet Estonian 27-06-2022
Public Assessment Report Public Assessment Report Estonian 15-06-2018
Patient Information leaflet Patient Information leaflet Greek 27-06-2022
Public Assessment Report Public Assessment Report Greek 15-06-2018
Patient Information leaflet Patient Information leaflet English 27-06-2022
Public Assessment Report Public Assessment Report English 15-06-2018
Patient Information leaflet Patient Information leaflet French 27-06-2022
Public Assessment Report Public Assessment Report French 15-06-2018
Patient Information leaflet Patient Information leaflet Italian 27-06-2022
Public Assessment Report Public Assessment Report Italian 15-06-2018
Patient Information leaflet Patient Information leaflet Latvian 27-06-2022
Public Assessment Report Public Assessment Report Latvian 15-06-2018
Patient Information leaflet Patient Information leaflet Lithuanian 27-06-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 27-06-2022
Public Assessment Report Public Assessment Report Lithuanian 15-06-2018
Patient Information leaflet Patient Information leaflet Hungarian 27-06-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 27-06-2022
Public Assessment Report Public Assessment Report Hungarian 15-06-2018
Patient Information leaflet Patient Information leaflet Dutch 27-06-2022
Public Assessment Report Public Assessment Report Dutch 15-06-2018
Patient Information leaflet Patient Information leaflet Polish 27-06-2022
Public Assessment Report Public Assessment Report Polish 15-06-2018
Patient Information leaflet Patient Information leaflet Portuguese 27-06-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 27-06-2022
Public Assessment Report Public Assessment Report Portuguese 15-06-2018
Patient Information leaflet Patient Information leaflet Romanian 27-06-2022
Public Assessment Report Public Assessment Report Romanian 15-06-2018
Patient Information leaflet Patient Information leaflet Slovak 27-06-2022
Public Assessment Report Public Assessment Report Slovak 15-06-2018
Patient Information leaflet Patient Information leaflet Slovenian 27-06-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 27-06-2022
Public Assessment Report Public Assessment Report Slovenian 15-06-2018
Patient Information leaflet Patient Information leaflet Finnish 27-06-2022
Public Assessment Report Public Assessment Report Finnish 15-06-2018
Patient Information leaflet Patient Information leaflet Swedish 27-06-2022
Public Assessment Report Public Assessment Report Swedish 15-06-2018
Patient Information leaflet Patient Information leaflet Norwegian 27-06-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 27-06-2022
Patient Information leaflet Patient Information leaflet Icelandic 27-06-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 27-06-2022
Patient Information leaflet Patient Information leaflet Croatian 27-06-2022
Public Assessment Report Public Assessment Report Croatian 15-06-2018

Search alerts related to this product

View documents history